Preclinical data was published today on research performed by Cytori Therapeutics (NASDAQ:CYTX) showing adipose (fat)-derived stem and regenerative cells (ADRCs), either fresh or banked, demonstrated statistically significant improvements in animal survival and kidney function in an acute kidney injury animal model. Complete results appear in the latest issue of Nephrology Dialysis Transplantation, available for download at http://ndt.oxfordjournals.org.
Two separate controlled studies were performed. One compared a mixed population of uncultured rodent ADRCs, delivered immediately after extraction (fresh cells), to a control group>
Acute kidney injury was induced by occluding blood flow into and out of both kidneys for 38 minutes. Twenty minutes after reperfusion of the kidneys, 5 x 106 ADRCs or saline only were injected intra-arterially. All rodents were assessed daily for seven days for markers of kidney function (serum creatinine and blood urea nitrogen) and survival.
In the fresh ADRC arm, 100% of the treated group survived after seven days, compared to only 57% of the control group (p = 0.005). In the banked ADRC arm, 90% of the treated group survived after seven days, compared to 33% in the control group (p = 0.019).
The ADRC-treated subjects showed statistically significant improvements in kidney function, as measured by serum creatinine (p<0.0001 in fresh; p<0.05 in banked) and blood urea nitrogen levels (p<0.0001 in fresh, p<0.05 in banked).
In addition, substantial improvement in the histologic structure within the kidney was observed as measured by a reduction in tubular cell death and epithelial shedding (p<0.0001).
Novel multi-biomarker approach enhances chronic kidney disease risk assessment